Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 12, pp. 1399-1410
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
Ke-Yu Shen, Ying Zhu, Sun‐Zhe Xie, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 41
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Abid Suddle, Helen L. Reeves, Richard Hubner, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1235-1268
Open Access | Times Cited: 18
Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC
Yuanxiang Lu, Jinghan Zhu, Yuxin Zhang, et al.
Advanced Science (2024)
Open Access | Times Cited: 18
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Manshi Yang, Mengying Cui, Yang Sun, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 16
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 13
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
Richard Finn, Baek‐Yeol Ryoo, Chiun Hsu, et al.
The Lancet Oncology (2025)
Open Access | Times Cited: 7
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
Da Xu, Hongwei Wang, Qun Ma, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 2
Advances in Immunotherapy in Hepatocellular Carcinoma
Matthew B. Bloom, S. Podder, Hien Dang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 2
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Vishnu Nagalapuram, Niveditha Popuri, Ryan David Nipp, et al.
JCO Oncology Practice (2025)
Closed Access | Times Cited: 2
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
Stephen L. Chan, Baek‐Yeol Ryoo, Frankie Mo, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 258-264
Closed Access | Times Cited: 16
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
Shunzhen Zheng, Siew Wee Chan, Fei Liu, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1582-1582
Open Access | Times Cited: 15
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
Xu Li, Jinzhang Chen, Chang Liu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 12
Immunotherapy for hepatocellular carcinoma
Alexa Childs, Gloryanne Aidoo-Micah, Mala K. Maini, et al.
JHEP Reports (2024) Vol. 6, Iss. 10, pp. 101130-101130
Closed Access | Times Cited: 12
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Rafał Becht, Kajetan Kiełbowski, Michał Wasilewicz
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1456-1456
Open Access | Times Cited: 11
The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers
Angelika M. Starzer, Ladislaia Wolff, Petar Popov, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102718-102718
Open Access | Times Cited: 10
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 9
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, et al.
Future Oncology (2024) Vol. 20, Iss. 28, pp. 2049-2057
Open Access | Times Cited: 9
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
Huaxiang Wang, Junjun Li, Xiuling Zhu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top